Sonja Marinovic
Overview
Explore the profile of Sonja Marinovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jelencic V, Sestan M, Kavazovic I, Lenartic M, Marinovic S, Holmes T, et al.
Nat Immunol
. 2024 Nov;
26(1):146.
PMID: 39562744
No abstract available.
2.
Trifinopoulos J, List J, Klampfl T, Klein K, Prchal-Murphy M, Witalisz-Siepracka A, et al.
Haematologica
. 2024 Oct;
PMID: 39385738
Despite major therapeutic advances in the treatment of acute lymphoblastic leukemia (ALL), resistances and long-term toxicities still pose significant challenges. Cyclins and their associated cyclin-dependent kinases are one focus of...
3.
Marinovic S, Derfi K, Skrtic A, Poljak M, Kapitanovic S
Genes (Basel)
. 2024 Aug;
15(8).
PMID: 39202367
MicroRNAs (miRNAs) are critical post-transcriptional gene regulators and their involvement in sporadic colon cancer (CRC) tumorigenesis has been confirmed. In this study we investigated differences in miRNA expression in microsatellite...
4.
List J, Gattringer J, Huszarek S, Marinovic S, Neubauer H, Kudweis P, et al.
Biomed Pharmacother
. 2024 Jul;
177:117057.
PMID: 38976957
Cyclotides are head-to-tail cyclized peptides with a unique cystine-knot motif. Their structure provides exceptional resistance against enzymatic, chemical, or thermal degradation compared to other peptides. Peptide-based therapeutics promise high specificity,...
5.
Mladenic K, Lenartic M, Marinovic S, Polic B, Wensveen F
Eur J Immunol
. 2024 Feb;
54(4):e2149641.
PMID: 38314819
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly common complication of obesity, affecting over a quarter of the global adult population. A key event in the pathophysiology of MASLD...
6.
Marinovic S, Lenartic M, Mladenic K, Sestan M, Kavazovic I, Benic A, et al.
Sci Immunol
. 2023 Sep;
8(87):eadd1599.
PMID: 37774007
Metabolic-associated fatty liver disease (MAFLD) is a spectrum of clinical manifestations ranging from benign steatosis to cirrhosis. A key event in the pathophysiology of MAFLD is the development of nonalcoholic...
7.
Cigrovski Berkovic M, Ulamec M, Marinovic S, Balen I, Mrzljak A
World J Clin Cases
. 2022 Jul;
10(16):5124-5132.
PMID: 35812675
Insulinomas are the most frequent type of functional pancreatic neuroendocrine tumors with a variety of neuroglycopenic and autonomic symptoms and well-defined diagnostic criteria; however, prediction of their clinical behavior and...
8.
Sadeghi Hassanabadi N, Broux B, Marinovic S, Gotthardt D
Front Immunol
. 2022 Jul;
13:909275.
PMID: 35784374
Multiple sclerosis (MS) is a highly debilitating autoimmune disease affecting millions of individuals worldwide. Although classically viewed as T-cell mediated disease, the role of innate lymphoid cells (ILC) such as...
9.
Marinovic S, Cigrovski Berkovic M, Zjacic-Rotkvic V, Kapitanovic S
Cancer Genet
. 2022 Jul;
266-267:44-50.
PMID: 35777127
Objectives: Pancreatic neuroendocrine tumors (NETs) are rare and account for about 7% of all cancers occurring in the pancreas. The epidermal growth factor family of receptors and their ligands play...
10.
Curio S, Jonsson G, Marinovic S
Immunother Adv
. 2021 Oct;
1(1):ltab018.
PMID: 34604863
Cancer immunotherapies have significantly improved patient survival and treatment options in recent years. Nonetheless, the success of immunotherapy is limited to certain cancer types and specific subgroups of patients, making...